4.8 Article

Human Gut-Derived Commensal Bacteria Suppress CNS Inflammatory and Demyelinating Disease

期刊

CELL REPORTS
卷 20, 期 6, 页码 1269-1277

出版社

CELL PRESS
DOI: 10.1016/j.celrep.2017.07.031

关键词

-

资金

  1. Department of Defense (DOD) [W81XWH-10- 1-0254]
  2. National Multiple Sclerosis Society (NMSS) [RG 5138A1/1T]
  3. National Multiple Sclerosis Society [RG 5138A1/1T]
  4. BioFire
  5. Check-Points
  6. Curetis
  7. 3M
  8. Merck
  9. Roche
  10. Qvella
  11. Diaxonhit
  12. ASM
  13. IDSA
  14. NIH [GM092993, NS048357, NS073684]
  15. NIH CTSA [RR024150, TR000135]
  16. Novartis Pharmaceuticals
  17. European Regional Development Fund (FNUSA-ICRC) [CZ.1.05/1.1.00/02.0123]
  18. Applebaum
  19. Hilton
  20. Peterson
  21. McNeilus Foundations

向作者/读者索取更多资源

The human gut is colonized by a large number of microorganisms (similar to 10(13) bacteria) that support various physiologic functions. A perturbation in the healthy gut microbiome might lead to the development of inflammatory diseases, such as multiple sclerosis (MS). Therefore, gut commensals might provide promising therapeutic options for treating MS and other diseases. We report the identification of human gut-derived commensal bacteria, Prevotella histicola, which can suppress experimental autoimmune encephalomyelitis (EAE) in a human leukocyte antigen (HLA) class II transgenic mouse model. P. histicola suppresses disease through the modulation of systemic immune responses. P. histicola challenge led to a decrease in pro-inflammatory Th1 and Th17 cells and an increase in the frequencies of CD4(+) FoxP3(+) regulatory T cells, tolerogenic dendritic cells, and suppressive macrophages. Our study provides evidence that the administration of gut commensals may regulate a systemic immune response and may, therefore, have a possible role in treatment strategies for MS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据